GAINESVILLE -
'There continues to be a significant unmet need for therapeutic solutions to treat early onset Alzheimer's disease. We are continuing to build momentum in our early AD clinical study evaluating Trappsol Cyclo and continue to believe in its potential to address the unmet medical need that patients, families and physicians are facing. We are pleased to add this now issued patent and remain committed to bolstering our patent estate covering Trappsol Cyclo,' commented
About
Safe Harbor Statement
This press release contains 'forward-looking statements' about the company's current expectations about future results, performance, prospects and opportunities, including, without limitation, statements regarding the satisfaction of closing conditions relating to the offering and the anticipated use of proceeds from the offering. Statements that are not historical facts, such as 'anticipates,' 'believes' and 'expects' or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the company's future performance include the company's ability to obtain additional capital to expand operations as planned, success in achieving regulatory approval for clinical protocols, enrollment of adequate numbers of patients in clinical trials, unforeseen difficulties in showing efficacy of the company's biopharmaceutical products, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing pharmaceutical grade and food products. These and other risk factors are described from time to time in the company's filings with the
Contact:
Tel: (833) 475-8247
Email: CYTH@jtcir.com
(C) 2024 Electronic News Publishing, source